• 16 June, 2025

Glargine trial promising for Mylan, Biocon

September 18, 2014 | Thursday | News | By BioSpectrum Bureau

Glargine trial promising for Mylan, Biocon

(Photo Courtesy: www.liferaftgroup.org)

(Photo Courtesy: www.liferaftgroup.org)

Glargine was developed by India's Biocon which was out-licensed to Mylan for further development.

According to Mylan, the trials have been initiated in August 2014 and is expected to culminate in June 2016.

The market for this drug is expected to be $3-4 billion worldwide.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy